The clinical efficacy of heteronemin in the therapy of cancer may be potentiated by inhibiting the cell surface receptors, such as integrin and EGFR, for nonpeptide hormone, as well as receptors for several other endogenous factors that are able to suppress the antiproliferation activity of heteronemin. This evidence concerns the gene CD177 and cancer.